The primary objective of this study is to evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge. Secondary objectives include evaluating the impact of buspirone, relative to placebo, on other drug-abuse outcomes and on factors that may mediate buspirone's efficacy as a relapse-prevention treatment.
Principal Investigator(s)
Theresa Winhusen, Ph.D.
Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
winhust@ucmail.uc.edu
Participating Sites
- Maryhaven, Inc., Ohio
- Addiction Medicine Services, Pennsylvania
- Penn Presbyterian Medical Center, Delaware
- Gateway Health Systems, Florida
- Lexington/Richland Alcohol and Drug Abuse Council, South Carolina
- Morris Village Alcohol and Drug Treatment Center, South Carolina
- Nexus Recovery Center, Inc., Texas